Ceribell, Inc. Files S-1 for Public Offering

Ticker: CBLL · Form: S-1 · Filed: Aug 26, 2024 · CIK: 1861107

Ceribell, INC. S-1 Filing Summary
FieldDetail
CompanyCeribell, INC. (CBLL)
Form TypeS-1
Filed DateAug 26, 2024
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$2 billion, $45.2 million, $25.9 million, $29.7 million, $20.5 million
Sentimentneutral

Sentiment: neutral

Topics: ipo, s-1, medical-device

TL;DR

Ceribell just filed its S-1, looks like they're going public!

AI Summary

Ceribell, Inc. filed an S-1 registration statement on August 26, 2024, to offer its securities. The company, incorporated in Delaware with its principal executive offices at 360 N. Pastoria Avenue, Sunnyvale, California, operates in the electromedical and electrotherapeutic apparatus industry. Jane Chao, Ph.D., serves as President, CEO, and Co-Founder.

Why It Matters

This S-1 filing indicates Ceribell, Inc. is preparing to become a publicly traded company, which could impact its growth, funding, and market presence in the medical device sector.

Risk Assessment

Risk Level: medium — As a company preparing for an IPO, Ceribell faces typical risks associated with market volatility, regulatory hurdles, and the need to demonstrate profitability and growth potential to investors.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of this S-1 filing?

The S-1 filing is a registration statement filed with the U.S. Securities and Exchange Commission to register securities for public offering.

When was this S-1 filing submitted?

The S-1 filing was submitted on August 26, 2024.

Who is the President, CEO, and Co-Founder of Ceribell, Inc. mentioned in the filing?

Jane Chao, Ph.D. is listed as the President, Chief Executive Officer and Co-Founder of Ceribell, Inc.

What is the primary business address of Ceribell, Inc.?

The primary business address is 360 N. Pastoria Avenue, Sunnyvale, California 94085.

Which law firm is listed as providing copies for this filing?

Latham & Watkins LLP is listed as providing copies for this filing.

Filing Stats: 4,384 words · 18 min read · ~15 pages · Grade level 15.4 · Accepted 2024-08-26 16:43:03

Key Financial Figures

Filing Documents

Description of Capital Stock

Description of Capital Stock 160 Special Note Regarding Forward-Looking Statements 58 Shares Eligible for Future Sale 165 Material U.S. Federal Income Tax Consequences to Non-U.S. Holders 168 Market and Industry Data 60

Use of Proceeds

Use of Proceeds 61

UNDERWRITING

UNDERWRITING 171 Dividend Policy 62 Legal Matters 178 Capitalization 63 Experts 178

Dilution

Dilution 65 Where You Can Find Additional Information 178 Management’s Discussion and Analysis of Financial Condition and Results of Operations 68 CHANGE IN INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 178

Business

Business 87 Index to Financial Statements F- 1 Management 135 As used in this prospectus, unless the context otherwise requires, references to “Ceribell,” the “company,” “we,” “us,” and “our” refer to CeriBell, Inc. “Ceribell,” the Ceribell logos, and other trade names, trademarks, or service marks of Ceribell appearing in this prospectus are the property of Ceribell. Other trade names, trademarks, or service marks appearing in this prospectus are the property of their respective holders. We do not intend our use or display of other companies’ trade names, trademarks, or service marks to imply a relationship with, or endorsement or sponsorship of us, by these other companies. Solely for convenience, trade names, trademarks, and service marks referred to in this prospectus appear without the , , and SM symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner will not assert its rights, to these trade names, trademarks, and service marks. Numerical figures included in this prospectus have been subject to rounding adjustments. Accordingly, numerical figures shown as totals in various tables may not be arithmetic aggregations of the figures that precede them. We have not, and the underwriters have not, authorized anyone to provide you any information or to make any representations other than those contained in this prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. Neither we nor the underwriters take responsibility for, or provide any assurance as to the reliability of, any other information others may give you. This prospectus is an offer to sell only the shares offered hereby, and only under circumstances and in jurisdictions where it is lawful to do so. We are not, and the underw

View Full Filing

View this S-1 filing on SEC EDGAR

View on Read The Filing